

Docket No. 240988US0CIP



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Tony MARCEL, et al.

SERIAL NO: 10/024,535

GAU: 1647

FILED: December 21, 2001

EXAMINER: S. Wegert

FOR: THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPAIRED INTERPERSONAL AND BEHAVIORAL DISORDERS

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon


---

Thomas M. Cunningham  
Registration No. 45,394

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
240988US0CIPSERIAL NO.  
10/024,535

## LIST OF REFERENCES CITED BY APPLICANT

APPLICANT  
Tony MARCEL, et al.FILING DATE  
December 21, 2001GROUP  
1647

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL |    | DOCUMENT<br>NUMBER | DATE | NAME | CLASS | SUB<br>CLASS | FILING DATE<br>IF APPROPRIATE |
|---------------------|----|--------------------|------|------|-------|--------------|-------------------------------|
|                     | AA |                    |      |      |       |              |                               |
|                     | AB |                    |      |      |       |              |                               |
|                     | AC |                    |      |      |       |              |                               |
|                     | AD |                    |      |      |       |              |                               |
|                     | AE |                    |      |      |       |              |                               |
|                     | AF |                    |      |      |       |              |                               |
|                     | AG |                    |      |      |       |              |                               |
|                     | AH |                    |      |      |       |              |                               |
|                     | AI |                    |      |      |       |              |                               |
|                     | AJ |                    |      |      |       |              |                               |
|                     | AK |                    |      |      |       |              |                               |
|                     | AL |                    |      |      |       |              |                               |
|                     | AM |                    |      |      |       |              |                               |
|                     | AN |                    |      |      |       |              |                               |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT<br>NUMBER | DATE | COUNTRY | TRANSLATION |    |
|--|----|--------------------|------|---------|-------------|----|
|  |    |                    |      |         | YES         | NO |
|  | AO |                    |      |         |             |    |
|  | AP |                    |      |         |             |    |
|  | AQ |                    |      |         |             |    |
|  | AR |                    |      |         |             |    |
|  | AS |                    |      |         |             |    |
|  | AT |                    |      |         |             |    |
|  | AU |                    |      |         |             |    |
|  | AV |                    |      |         |             |    |

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

|  |    |  |  |  |  |   |
|--|----|--|--|--|--|---|
|  | AW | "Diagnostic and Statistical Manual of Mental Disorders", The American Psychiatric Association (author), 4 <sup>th</sup> Edition                        |  |  |  |   |
|  | AX | Fasano A., "Innovative strategies for the oral delivery of drugs and peptides", Trends Biotechnol., 1998 Apr; 16(4):152-7 (Abstract only).             |  |  |  |   |
|  | AY | Pontioli AE., "Peptide hormones: Review of current and emerging uses by nasal delivery", Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):81-87 (Abstract only). |  |  |  |   |
|  | AZ | Leopold CS., "[Targeted delivery] in the gastrointestinal tract]", Med Klin (Munich). 1999 Feb 15;94 Suppl 1:6-11 (Abstract only).                     |  |  |  | <input checked="" type="checkbox"/> Additional References sheet(s) attached |

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|  |     |   |  |                                      |                 |                              |  |
|--|-----|---|--|--------------------------------------|-----------------|------------------------------|--|
| Form PTO 1449<br>(Modified)  |     | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE  |  | ATTY DOCKET NO.<br><br>240988US0CIP  |                 | SERIAL NO.<br><br>10/024,535 |  |
| LIST OF REFERENCES CITED BY APPLICANT  |     |   |  | APPLICANT<br><br>Tony MARCEL, et al. |                 |                              |  |
|  |     |   |  | FILING DATE<br><br>December 21, 2001 |                 | GROUP<br><br>1647            |  |
| <b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>   |     |   |  |                                      |                 |                              |  |
|  | AAA | Rougeot C., et al., "Sialorphan, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.", Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8549-54. Epub 2003 June 30. |  |                                      |                 |                              |  |
|  | AAB | Messaoudi M., et al., "The endogenous androgen-regulated sialorphan modulates male rat sexual behavior.", Horm Behav. 2004 Dec;46(5):684-91.  |  |                                      |                 |                              |  |
|  | AAC | A. Argiolas, "Neuropeptides and sexual behaviour", Neuroscience and Biobehavioral Reviews 23 (1999) 1127-1142.  |  |                                      |                 |                              |  |
|  | AAD | M. Messaoudi, et al., "The endogenous androgen-regulated sialorphan modulates male rat sexual behavior", Hormones and Behavior 46 (2004) 684-691.   |  |                                      |                 |                              |  |
|  | AAE | Catherine Rougeot, et al., "Sialorphan, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity", PNAS, July 8, 2003, vol. 100, no. 14, pp. 8549-8554.             |  |                                      |                 |                              |  |
|  | AAF |   |  |                                      |                 |                              |  |
|  | AAG |   |  |                                      |                 |                              |  |
|  | AAH |   |  |                                      |                 |                              |  |
|  | AAI |   |  |                                      |                 |                              |  |
|  | AAJ |   |  |                                      |                 |                              |  |
|  | AAK |   |  |                                      |                 |                              |  |
|  | AAL |   |  |                                      |                 |                              |  |
|  | AAM |   |  |                                      |                 |                              |  |
|  | AAN |   |  |                                      |                 |                              |  |
|  | AAO |   |  |                                      |                 |                              |  |
|  | AAP |   |  |                                      |                 |                              |  |
|  | AAQ |   |  |                                      |                 |                              |  |
| Examiner   |     |   |  |                                      | Date Considered |                              |  |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |     |   |  |                                      |                 |                              |  |